Shufeng Xingbi Therapy Modulates Immune Balance and Gut Flora in AR Rats

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent, non-infectious chronic inflammatory condition of the nasal mucosa, affecting over 10% of the global population. Its pathogenesis is primarily driven by an imbalance in T helper 1 (Th1)/T helper 2 (Th2) immune responses, with a skew toward Th2 dominance and increased IgE production following allergen exposure. Conventional pharmacotherapies—such as glucocorticoids, antihistamines, and leukotriene receptor antagonists—offer symptomatic relief but often entail adverse effects and do not address the underlying immune dysregulation or associated gut microbiota alterations. Increasing evidence links the composition of intestinal flora and their metabolic products, particularly short-chain fatty acids (SCFAs), to immune homeostasis and allergic disease development. The reference study (Yan et al., 2025) interrogates whether Shufeng Xingbi Therapy (SFXBT), a traditional Chinese medicine regimen, can restore Th1/Th2 balance and beneficially modulate gut microbiota in an OVA-induced AR rat model, providing a mechanistic basis for integrative therapeutic strategies.

Key Innovation from the Reference Study

The principal innovation of Yan et al. lies in the dual interrogation of immune and microbial endpoints following SFXBT intervention in AR. The study uniquely combines quantitative immunological profiling (serum IgE, IL-4, STAT5/STAT6/GATA3 expression) with high-resolution 16S rDNA-based gut microbiota analysis and functional readouts (SCFA quantification). This integrated approach enables the dissection of SFXBT’s mechanistic impact not only on nasal mucosal inflammation but also on systemic immunomodulation and microbiota-host crosstalk. Notably, the inclusion of both antibiotic-pretreated and acetic acid-pretreated SFXBT groups allows for parsing the contribution of microbial context to therapeutic efficacy, underscoring the interplay between antibiotic-induced dysbiosis and immune restoration.

Methods and Experimental Design Insights

The researchers employed a robust experimental design involving 32 male Sprague-Dawley rats, randomly allocated into four groups: control, OVA-induced AR, antibiotic+SFXBT, and acetic acid+SFXBT. Allergic rhinitis was induced via repeated ovalbumin sensitization and challenge, mirroring human atopic exposure. SFXBT was administered both orally (decoction) and intranasally (gel), reflecting its clinical use. Key endpoints were evaluated as follows:

• Behavioral assessment of AR severity through symptom scoring.
• Histopathological analysis of nasal mucosa via hematoxylin and eosin staining.
• Microbiota profiling of colonic content using 16S rDNA sequencing.
• Quantification of serum IgE, IL-4, and SCFAs by ELISA.
• mRNA and protein expression analyses (STAT5, STAT6, GATA3, IL-4) in nasal mucosa by RT-qPCR and Western blotting.

This multi-tiered approach provides a detailed landscape of both immunological and microbial alterations.

Protocol Parameters

• OVA-induced AR: Sensitize rats with repeated ovalbumin injections, followed by intranasal OVA challenge to elicit AR symptoms.
• Antibiotic regimen: Use glycopeptide antibiotics (e.g., Vancomycin) for microbiota depletion prior to SFXBT intervention, to assess the role of gut flora in modulating immune responses.
• SFXBT administration: Provide both oral decoction and intranasal gel to model clinical therapeutic use.
• 16S rDNA sequencing: Collect colonic content post-intervention for microbial profiling, focusing on phylum and genus-level changes.
• ELISA and molecular analyses: Quantify serum cytokines and perform nasal mucosal RT-qPCR/Western blot for immune mediator expression.

Researchers are encouraged to tailor pretreatment durations and dosing regimens based on the specifics of their AR model and desired endpoints.

Core Findings and Why They Matter

The reference study (Yan et al., 2025) demonstrates that SFXBT markedly reduces AR behavioral scores and mitigates nasal mucosal pathology compared to the OVA group. Immune profiling reveals significant reductions in serum IgE and IL-4, with corresponding decreases in the transcription and protein levels of STAT5, STAT6, and GATA3 in nasal tissues—indicative of a restored Th1/Th2 balance and dampened allergic inflammation.

Microbiota analysis further shows a substantial shift at both the phylum and genus levels: Firmicutes abundance rises, while Bacteroidetes decreases. Notably, the genera Lactobacillus, Romboutsia, Allobaculum, and Dubosiella are enriched following SFXBT, paralleling an increase in fecal SCFA concentrations. These changes are functionally significant, as SCFAs are known to exert immunoregulatory effects and support mucosal barrier function. The antibiotic+SFXBT group, in particular, underscores the necessity of an intact or partially restored microbiota for optimal immune modulation, as antibiotic pretreatment alters the therapeutic trajectory.

Together, these findings illuminate a mechanistic axis wherein SFXBT alleviates allergic inflammation by both directly modulating immune effector pathways and indirectly shaping the gut microbial milieu to favor anti-inflammatory metabolite production.

Comparison with Existing Internal Articles

Several internal articles, such as "Vancomycin: Advanced Insights into Glycopeptide Antibiotic" and "Vancomycin as a Translational Lever", elaborate on the use of Vancomycin as a glycopeptide antibiotic for mechanistic studies of bacterial resistance and immune-microbiota interactions. Both highlight Vancomycin's principal action as a bacterial cell wall synthesis inhibitor via D-Ala-D-Ala binding—a property leveraged to experimentally deplete or modulate gut flora. The reference study aligns with these principles, employing glycopeptide antibiotics to dissect the contribution of microbiota to immune responses in AR. Where the internal resources focus on MRSA and Clostridium difficile infection research, Yan et al. extend this experimental paradigm to allergic and immune-microbiota models, demonstrating the broader applicability of such antibiotic tools.

Furthermore, internal discussions (see here) on peptidoglycan precursor binding and workflow optimization for microbiota studies provide a methodological bridge to the reference paper’s antibiotic-intervention arm, supporting the cross-domain use of Vancomycin for both resistance mechanism and immune-microbiota research.

Limitations and Transferability

Despite its robust design, the study has limitations. The AR model is restricted to rats, and interspecies differences may constrain direct extrapolation to human disease. The complexity of SFXBT’s herbal constituents may introduce variability in composition and bioactivity, challenging reproducibility outside of controlled settings. Furthermore, while the study profiles key microbial taxa and immune mediators, it does not establish direct causality between specific microbiota shifts and immune outcomes. Long-term effects, safety, and optimal dosing strategies for SFXBT in combination with antibiotics remain to be elucidated. Nonetheless, the findings provide a valuable experimental scaffold for future translational studies investigating immune-microbiota interplay using similar methodologies.

Research Support Resources

For researchers aiming to model antibiotic-induced gut microbiota perturbation or to investigate immune-microbiota interactions in allergy and resistance studies, high-purity glycopeptide antibiotics are essential. Vancomycin (SKU C6417) from APExBIO, with its well-characterized mechanism of peptidoglycan precursor binding and proven solubility in DMSO, is suitable for experimental workflows requiring microbiota depletion or the study of bacterial cell wall synthesis inhibition. Its utility in MRSA, Clostridium difficile infection research, and immune-microbiota models aligns with the protocols described in Yan et al. Researchers should consult current product information for details on solubility, purity, and storage to ensure reproducible results.